Recent 8-K filings for RAPP

• June 10, 2026, 4:12 PM ET other materiality 0.15 neutral item 5.07 ◈ Shareholder Votes ×2

  Rapport Therapeutics stockholders elect three Class II directors and ratify PwC as auditor

  James Healy, M.D., Ph.D. elected with 41,762,713 for, 587,163 withheld; broker non-votes 1,983,035.

• May 7, 2026, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01 ◈ Earnings Releases

  Rapport Q1 net loss $19.9M, cash $476.8M; RAP-219 Phase 3 in FOS on track for Q2 2026

  Net loss $19.9M (vs $24.1M YoY); collaboration revenue $20.0M from Tenacia deal.

• April 21, 2026, 7:59 PM ET other material materiality 0.85 positive item 7.01item 8.01item 9.01

  RAP-219 Phase 2a follow-up shows sustained seizure reduction; half-life updated to ~22 days

  90% median reduction in clinical seizures in weeks 9-12; 59% in weeks 13-16, demonstrating sustained effect after treatment cessation.

• March 10, 2026, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01 ◈ Earnings Releases

  Rapport Therapeutics reports FY2025 net loss $111.5M, RAP-219 Phase 2 positive, Phase 3 Q2 2026

  Net loss Q4 2025 $33.8M, full year $111.5M; R&D expenses $94.8M FY2025 vs $60.9M FY2024.

• January 7, 2026, 6:59 PM ET other material materiality 0.65 positive item 7.01item 8.01item 9.01

  Rapport accelerates Phase 3 start for RAP-219 in focal seizures to Q2 2026; expands epilepsy portfolio into PGTCS

  Phase 3 program for RAP-219 in focal onset seizures accelerated to Q2 2026 (from Q3) after FDA End-of-Phase 2 meeting.

• January 7, 2026, 6:59 PM ET other material materiality 0.50 neutral item 8.01item 9.01

  Rapport Therapeutics registers up to $110M in at-the-market stock offering

  Filed prospectus supplement on Jan 7, 2026 to sell up to $110M of common stock through Leerink and Cantor Fitzgerald.

• November 6, 2025, 6:59 PM ET other material materiality 0.85 positive item 2.02item 9.01

  Rapport: Phase 2a RAP-219 meets endpoints; 77.8% median seizure reduction; Q3 net loss $26.9M

  Phase 2a in drug-resistant focal seizures: 77.8% median clinical seizure reduction, 24% seizure freedom, 85.2% with ≥30% LE reduction (all p<0.01).

• September 10, 2025, 7:59 PM ET other material materiality 0.65 neutral item 1.01item 9.01

  Rapport Therapeutics announces $234.7M public offering of 9.6M shares at $26.00 per share

  Underwriting agreement for 9,615,385 shares at $26.00; underwriters option for up to 1,442,307 additional shares.

• September 8, 2025, 7:59 PM ET other material materiality 0.85 positive item 7.01item 8.01item 9.01

  Rapport RAP-219 Phase 2a positive: 85.2% achieved ≥30% LE reduction, 24% seizure freedom

  85.2% of patients achieved ≥30% reduction in long episodes (p<0.0001); median LE reduction 71%.

• September 8, 2025, 7:59 PM ET other material materiality 0.10 neutral item 8.01item 9.01

  Rapport Therapeutics terminates ATM equity offering program; no shares sold

  Effective Sept 8, 2025, terminated the ATM prospectus under the S-3 registration statement.

• August 7, 2025, 7:59 PM ET earnings materiality 0.55 neutral item 2.02item 7.01item 9.01

  Rapport Therapeutics Q2 net loss $26.7M; RAP-219 Phase 2a topline due Sept 2025, cash runway through 2026

  Net loss of $26.7M for Q2 2025 vs $18.1M YoY; R&D expenses $22.7M and G&A $6.8M.

• June 18, 2025, 7:59 PM ET other material materiality 0.10 neutral item 5.07

  Rapport Therapeutics stockholders re-elect three Class I directors and ratify PwC as auditor

  Reid Huber, Ph.D., John Maraganore, Ph.D., and Wendy B. Young, Ph.D. elected as Class I directors for terms expiring 2028.

• June 2, 2025, 7:59 PM ET other material materiality 0.70 positive item 7.01item 8.01item 9.01

  RAP-219 Phase 2a fully enrolled; topline data Sept 2025; safety profile clean

  Phase 2a trial of RAP-219 in refractory focal epilepsy fully enrolled; topline results expected September 2025.

• May 8, 2025, 7:59 PM ET earnings materiality 0.50 neutral item 2.02item 9.01

  Rapport Therapeutics Q1 net loss $24.1M; RAP-219 epilepsy trial on track for Q3 2025 data

  Net loss $24.1M in Q1 2025 vs $22.7M prior year; R&D expenses rose to $19.6M from $12.5M.

• March 11, 2025, 7:59 PM ET earnings materiality 0.75 neutral item 2.02item 9.01

  Rapport Therapeutics FY2024 net loss $78.3M; RAP-219 epilepsy trial top line Q3 2025

  Net loss $78.3M for FY2024 vs $34.8M in FY2023; R&D expense $60.9M up from $28.0M.

• March 3, 2025, 6:59 PM ET leadership materiality 0.75 positive item 7.01item 8.01item 9.01

  Rapport hires Dr. Jeffrey Sevigny as CMO; Phase 2a data expected Q3 2025

  Jeffrey Sevigny, former CMO at Prevail Therapeutics (Eli Lilly), appointed CMO effective immediately.

• January 10, 2025, 6:59 PM ET other material materiality 0.60 neutral item 7.01item 8.01item 9.01

  Rapport reports positive Phase 1 RAP-219 data; CMO steps down

  PET trial: dosing regimen used in Phase 2a epilepsy trial exceeded target receptor occupancy (50-70%) within 5 days.

• November 7, 2024, 6:59 PM ET earnings materiality 0.70 negative item 2.02item 9.01

  Rapport Therapeutics Q3 net loss $17.5M; DPNP IND on clinical hold; cash $320.7M

  Net loss $17.5M vs $8.7M prior year; R&D expense $15.5M (up from $7.6M) driven by clinical development.

• August 8, 2024, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Rapport Therapeutics Q2 net loss $18.1M; cash $336.1M; IPO raised $174.4M gross

  Net loss $18.1M vs $6.4M YoY; R&D expense $15.7M vs $4.7M YoY.

• June 10, 2024, 7:59 PM ET other material materiality 0.90 positive item 1.01item 3.02item 5.03item 9.01

  Rapport Therapeutics closes private placement of 1,058,824 shares at $17.00 per share with existing stockholders

  Entered Stock Purchase Agreements with Sofinnova Venture Partners and affiliates of Goldman Sachs for 1,058,824 shares at $17.00/share, concurrent with IPO.

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.90 · Median 0.68 · Most common event other_material

9 positive 1 negative 10 neutral

source · RAPP on sec.gov